Division of Urology, Department of Surgery and of Surgical Oncology, Princess Margaret Hospital and the University Health Network, University of Toronto, Toronto, Ontario, Canada.
Eur Urol. 2011 Jul;60(1):39-44. doi: 10.1016/j.eururo.2011.03.030. Epub 2011 Apr 1.
Most early stage kidney cancers are renal cell carcinomas (RCCs), and most are diagnosed incidentally by imaging as small renal masses (SRMs). Indirect evidence suggests that most small RCCs grow slowly and rarely metastasize.
To determine the progression and growth rates for newly diagnosed SRMs stratified by needle core biopsy pathology.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter prospective phase 2 clinical trial of active surveillance of 209 SRMs in 178 elderly and/or infirm patients was conducted from 2004 until 2009 with treatment delayed until progression.
Patients underwent serial imaging and needle core biopsies.
We measured rates of change in tumor diameter (growth measured by imaging) and progression to ≥ 4 cm, doubling of tumor volume, or metastasis with histology on biopsy.
Local progression occurred in 25 patients (12%), plus 2 progressed with metastases (1.1%). Of the 178 subjects with 209 SRMs, 127 with 151 SRMs had>12 mo of follow-up with two or more images, with a mean follow-up of 28 mo. Their tumor diameters increased by an average of 0.13 cm/yr. Needle core biopsy in 101 SRMs demonstrated that the presence of RCC did not significantly change growth rate. Limitations included no central review of imaging and pathology and a short follow-up.
This is the first SRM active surveillance study to correlate growth with histology prospectively. In the first 2 yr, the rate of local progression to higher stage is low, and metastases are rare. SRMs appear to grow very slowly, even if biopsy proven to be RCC. Many patients with SRMs can therefore be initially managed conservatively with serial imaging, avoiding the morbidity of surgical or ablative treatment.
大多数早期肾癌为肾细胞癌(RCC),且大多数是通过影像学检查偶然发现的小肾肿块(SRM)。间接证据表明,大多数小 RCC 生长缓慢,很少转移。
根据针芯活检病理对新诊断的 SRM 进行分层,以确定其进展和生长速度。
设计、地点和参与者:2004 年至 2009 年,对 178 名老年和/或体弱患者的 209 个 SRM 进行了多中心前瞻性 2 期主动监测临床试验,在出现进展时才开始治疗,且将治疗延迟。
患者接受了连续影像学和针芯活检。
我们测量了肿瘤直径的变化率(通过影像学测量的生长)以及进展到≥4cm、肿瘤体积倍增或活检显示转移的情况。
25 名患者(12%)出现局部进展,其中 2 名进展时伴有转移(1.1%)。在 178 名患有 209 个 SRM 的患者中,127 名患有 151 个 SRM,随访时间超过 12 个月,有两个或更多图像,平均随访时间为 28 个月。他们的肿瘤直径平均每年增加 0.13cm。在 101 个 SRM 中进行的针芯活检表明,RCC 的存在并没有显著改变生长速度。局限性包括没有对影像学和病理学进行中心审查以及随访时间短。
这是第一项前瞻性地将生长与组织学相关联的 SRM 主动监测研究。在前 2 年,局部进展为更高阶段的比例较低,转移也很少见。SRM 似乎生长非常缓慢,即使活检证实为 RCC 也是如此。因此,许多 SRM 患者可以通过连续影像学检查进行保守治疗,避免手术或消融治疗的发病率。